Navicare Biotech Co., Ltd.

This report focuses on GOMAJI’s balance sheet and financial health, highlighting that total equity of about NT$270.5M is outweighed by total debt of roughly NT$324.2M, implying a leverage ratio near 119.9% and rising indebtedness over the last five years. It stresses that short-term assets do not cover short-term liabilities, operating cash flow is negative, and debt is not well-covered, leading to a cautious view on solvency risk and signaling that investors should be wary of the company’s ability to service obligations.

Macroaxis applies a multi-factor valuation model combining fundamentals such as market capitalization around NT$532M, dividend history, employee count, and modeled probability of bankruptcy with technical indicators to estimate a “Real Value” of roughly NT$57.88 per share versus a market price near NT$72.9, concluding that GOMAJI appears overvalued. The analysis frames this valuation gap as downside risk for investors and implies a negative or at best cautious stance on the shares, suggesting that current pricing does not adequately reflect fundamental risks.

This comprehensive analysis covers price performance, volatility, valuation, earnings, and leverage, noting that the share price has risen strongly over the past year but that trailing‑twelve‑month revenue of about NT$440M still translates into a net loss of around NT$44.5M and a negative net margin near −10%, alongside a debt‑to‑equity ratio above 120%. While the report acknowledges stable weekly volatility and the company’s e‑commerce business model, it emphasizes ongoing losses, high leverage, and balance‑sheet constraints without offering a clear buy or sell recommendation, resulting in a balanced but cautious overall outlook.